JP Morgan Chase’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-123
| Closed | -$556 | – | 7594 |
|
|
2025
Q4 | $556 | Sell |
123
-301,398
| -100% | -$1.54M | ﹤0.01% | 7074 |
|
|
2025
Q3 | $1.63M | Sell |
301,521
-12,424
| -4% | -$67.2K | ﹤0.01% | 4239 |
|
|
2025
Q2 | $1.7M | Buy |
+313,945
| New | +$1.25M | ﹤0.01% | 4031 |
|
|
2024
Q2 | – | Sell |
-93,038
| Closed | -$282K | – | 7408 |
|
|
2024
Q1 | $282K | Buy |
93,038
+21,730
| +30% | +$76.3K | ﹤0.01% | 5145 |
|
|
2023
Q4 | $300K | Buy |
71,308
+29,459
| +70% | +$160K | ﹤0.01% | 5104 |
|
|
2023
Q3 | $286K | Buy |
41,849
+31,882
| +320% | +$282K | ﹤0.01% | 4825 |
|
|
2023
Q2 | $104K | Buy |
+9,967
| New | +$89.1K | ﹤0.01% | 5435 |
|
|
2023
Q1 | – | Sell |
-418
| Closed | -$3K | – | 6778 |
|
|
2022
Q4 | $3K | Sell |
418
-10,955
| -96% | -$80.9K | ﹤0.01% | 6241 |
|
|
2022
Q3 | $90K | Sell |
11,373
-126,856
| -92% | -$1.48M | ﹤0.01% | 5328 |
|
|
2022
Q2 | $1.88M | Buy |
138,229
+115,412
| +506% | +$1.91M | ﹤0.01% | 3599 |
|
|
2022
Q1 | $448K | Buy |
22,817
+6,016
| +36% | +$120K | ﹤0.01% | 4771 |
|
|
2021
Q4 | $576K | Buy |
16,801
+6,085
| +57% | +$245K | ﹤0.01% | 4738 |
|
|
2021
Q3 | $585K | Buy |
10,716
+810
| +8% | +$48.8K | ﹤0.01% | 4639 |
|
|
2021
Q2 | $728K | Sell |
9,906
-34,695
| -78% | -$3.47M | ﹤0.01% | 4486 |
|
|
2021
Q1 | $4.08M | Buy |
44,601
+36,947
| +483% | +$3.58M | ﹤0.01% | 3145 |
|
|
2020
Q4 | $621K | Buy |
+7,654
| New | +$586K | ﹤0.01% | 4254 |
|
JP Morgan Chase's CVAC Position: Q1 2026 in Review
JP Morgan Chase sold out of CureVac (CVAC) in Q1 2026, closing a stake of 123 shares — an estimated $556 sold.
JP Morgan Chase first reported a position in CVAC in Q4 2020 and held it in 16 quarters. The position peaked at $4.08M in Q1 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- JP Morgan Chase reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 123 CureVac shares in Q1 2026, an estimated $556.
- JP Morgan Chase first reported a position in CureVac in Q4 2020 and held it in 16 quarters.
- JP Morgan Chase's CureVac position peaked at $4.08M in Q1 2021.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.